| For Practicing Rheumatologists |
See all
|
Article Summary
|
|
|
Hedrich CM et al. - We report the favourable response of a 23-year-old CINCA patient without CIAS1 mutations to treatment with the recombinant interleukin-1 (IL-1) receptor antagonist anakinra.
|
 |
 |
| Read a Different Specialty |
 |
|
|
|
 |
| Profession Index |
 |
|
|
|
 |
|
|